Ben-Ishay Z, Barak V
Department of Anatomy and Cell Biology, Hebrew University Hadassah Medical School and Immunology Laboratory for Tumor Diagnosis, Oncology Department, Hadassah Medical Center, Jerusalem, Israel.
Eur J Haematol. 2001 Apr;66(4):230-7. doi: 10.1034/j.1600-0609.2001.066004230.x.
The aim of the study was to investigate ex-vivo the bone marrow (BM) stroma of mice under conditions of low- and high-dose cytosine arabinoside (Ara-C), a cycle-specific drug (S-phase) and to assess possible stromal damage, apart from the killing of hematopoietic cells. Stroma consists of mesenchymal elements generally not in the cell cycle; therefore it could not be a target for the killing effect of Ara- C.
The stromal function was studied by the following: the incidence of stromal stem cells, i.e. CFU-F; formation of stromal layers under growth conditions of long-term culture (LTC) followed by irradiation and overlayering of test cells in contact and non-contact co-cultures; subsequent culture of the test cells in a semi-solid medium to assay the incidence of hyperproliferative potential cells (HPPC); production of GM-CSF, IL-3, IL-4, IL-6 and IFNgamma in the conditioned medium (CM) of confluent stromal layers. All tests and assays were carried out on BM specimens, 1-4 d after Ara-C administration and on controls.
Low-dose Ara-C induces a marked decrease of CFU-F, compensated by cycle induction of pre-CFU-F, young-type stromal stem cells. High-dose Ara-C causes a CFU-F decrease to almost zero level. The time length to layer confluency is normal after low-dose Ara-C ( approximately 10 d) and prolonged after a high dose ( approximately 30 d). The confluent layers from mice receiving low- or high-dose Ara-C support hematopoiesis adequately. Among the growth factors and cytokines assayed, only IL-6 is detected in CM layers. IL-6 decreases after a low dose of Ara-C and increases after a high dose. The cause of IL-6 fluctuations is yet to be investigated. It is, however, evident that IL-6 is not an essential factor in support of hematopoiesis.
Taken together, the current study in mice indicates that Ara-C administration, in particular a high dose, induces bone marrow stromal damage and/or disfunction. The long period of time to reach layer confluency after a high Ara-C dose might reflect the in-vivo situation of slow stromal regeneration.
本研究旨在体外研究低剂量和高剂量阿糖胞苷(Ara-C,一种作用于细胞周期特异性(S期)的药物)作用下小鼠的骨髓(BM)基质,除评估造血细胞的杀伤作用外,还评估可能的基质损伤。基质由通常不在细胞周期中的间充质成分组成;因此,它不可能是阿糖胞苷杀伤作用的靶点。
通过以下方法研究基质功能:基质干细胞的发生率,即集落形成单位-成纤维细胞(CFU-F);在长期培养(LTC)生长条件下形成基质层,随后进行照射,并在接触和非接触共培养中覆盖测试细胞;随后在半固体培养基中培养测试细胞,以测定高增殖潜能细胞(HPPC)的发生率;汇合基质层的条件培养基(CM)中粒细胞-巨噬细胞集落刺激因子(GM-CSF)、白细胞介素-3(IL-3)、白细胞介素-4(IL-4)、白细胞介素-6(IL-6)和干扰素γ(IFNγ)的产生。所有测试和分析均在阿糖胞苷给药后1-4天的骨髓标本及对照标本上进行。
低剂量阿糖胞苷导致CFU-F显著减少,但由前CFU-F(年轻型基质干细胞)的周期诱导得到补偿。高剂量阿糖胞苷导致CFU-F减少至几乎为零水平。低剂量阿糖胞苷后达到层汇合的时间长度正常(约10天),高剂量后延长(约30天)。接受低剂量或高剂量阿糖胞苷的小鼠的汇合层能够充分支持造血。在所检测的生长因子和细胞因子中,CM层中仅检测到IL-6。低剂量阿糖胞苷后IL-6减少,高剂量后增加。IL-6波动的原因尚待研究。然而,很明显IL-6不是支持造血的必需因子。
综上所述,目前在小鼠中的研究表明,阿糖胞苷给药,尤其是高剂量给药,会诱导骨髓基质损伤和/或功能障碍。高剂量阿糖胞苷后达到层汇合的长时间可能反映了体内基质再生缓慢的情况。